Relenza 'Dear Doctor' letter

Glaxo (GLX; LSE:GLXO) issued a "Dear Doctor" letter describing a warning added to the label of its Relenza zanamivir inhaled neuraminidase inhibitor to treat influenza. The product was developed in collaboration with Biota (ASX:BTA). The letter notes reports of bronchospasm and decline in lung function in some patients, many of whom had underlying airway diseases, and states that Relenza is generally not recommended in these patients. GLX said that adverse events in patients with a history of airway disease have included hospitalization and death. The label has been revised to reflect that serious respiratory adverse events have been reported in patients with or without known underlying respiratory disease. ...